Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOOTPATH: NAPOLI vs seq-NAPOLI-FOLFOX vs Gem/nab-Paclitaxel in Metastatic Pancreatic Cancer
NCT03487016Phase 2Unknown
- Sponsor
- Ludwig Maximilian University of Munich
- Start
- Feb 2019
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan in pancreatic adenocarcinoma (PDAC), sponsored by Ludwig Maximilian University of Munich. Status: unknown.
02
Drugs
irinotecan
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03487016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03487016.